ArticleCNS neuroscience & therapeutics2021
Large-scale whole-exome sequencing association study identifies FOXH1 gene and sphingolipid metabolism pathway influencing major depressive disorder.
Article in CNS neuroscience & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Sphingolipids in Emotional Well-Being.Journal of neurochemistry · 2026Review
- Article
- Mutational landscape of risk variants in comorbid depression and obesity: a next-generation sequencing approach.Molecular psychiatry · 2024Article
- Integration of whole-exome sequencing and structural neuroimaging analysis in major depressive disorder: a joint study.Translational psychiatry · 2024Article
- Genetic variations in the retrograde endocannabinoid signaling pathway in Chinese patients with major depressive disorder.Frontiers in neurology · 2023Article
- Major Depressive Disorder: Existing Hypotheses about Pathophysiological Mechanisms and New Genetic Findings.Genes · 2022Review
- Identification of putative genetic variants in major depressive disorder patients in Pakistan.Molecular biology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
In the present study, we performed an exome-wide investigation of the burden of rare disease-causing variants for major depressive disorder (MDD) using 16,702 samples from UK biobank. Gene-based association analysis and candidate gene prioritization analysis indicated that FOXH1 have significant association with MDD. In addition, sphingolipid metabolism pathway was found to be less enriched with rare disease-causing variants in the MDD group, suggesting that this gene set may be involved in the pathophysiology of MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.